Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
VZ$46.75+0.58(+1.26%)Verizon Makes the Holidays Simple with Our Best Deals and Rewards Just for Being a Customer8:01:25 AM ETSHEL$102.33+0.47(+0.46%)Transaction in Own Shares8:00:53 AM ETISRG$483.40+1.21(+0.25%)World’s First Fully Robotic Transoral Gastric Procedures Completed Using EndoQuest’s Endoluminal Surgical System8:00:00 AM ETAAPL$354.00+4.49(+1.28%)The new moto buds ultra 27 take audio up a notch with Sound by Bose technology and bring AI live translation to consumers8:00:00 AM ETTM$217.02+17.56(+8.80%)2027 Toyota Tundra: A Bold New Chapter in Full-Size Pickup Excellence with Advanced Towing Tech and the New Trailhunter Package8:00:00 AM ETIBM$256.25+1.93(+0.76%)Oak Ridge National Laboratory, IBM, and AMD Launch New Co-Design Platform for Quantum Error Correction8:00:00 AM ETAAPL$354.00+4.49(+1.28%)Apple: Demand Is Not The Problem7:54:50 AM ETMCD$282.00+1.78(+0.64%)McDonald's Is Rallying, but Can You Sleep at Night Owning It?7:48:44 AM ETPLTR$167.07-4.63(-2.70%)Palantir's CEO Just Said What Wall Street Doesn't Want to Hear About AI7:47:36 AM ETMSFT$557.00+1.20(+0.22%)The Same $10,000 in Microsoft and Meta Could Produce Very Different Results by 20307:47:14 AM ETQCOM$155.20-17.99(-10.39%)Wall Street Breakfast Podcast: The VIX Plunges In Post-Election Rally7:47:00 AM ETKO$97.10+1.22(+1.27%)If You'd Invested $1,000 Alongside Warren Buffett in Coca-Cola, Here's How Much You'd Have Today7:47:00 AM ETQCOM$155.20-17.99(-10.39%)Qualcomm Q4: This Dip Is Not The One To Buy Yet7:45:04 AM ETAXP$337.65+5.03(+1.51%)American Express vs. PayPal: Which Financial Stock Is a Better Buy for 2027?7:45:01 AM ETSPCX$132.50-3.42(-2.52%)Stack Capital Group Inc. Reports Q3-2026 Financial Results7:45:00 AM ETUBER$72.09+2.19(+3.13%)Amazon and Uber Want to Bring You Your Next Meal. The Delivery Turf War Is Escalating.7:43:00 AM ETCOP$139.45+2.51(+1.83%)BUZZ-ConocoPhillips rises on Q3 profit beat7:40:48 AM ETTGT$165.25+2.20(+1.35%)Target Looks More Attractive Than You'd Think7:31:07 AM ETCOP$139.45+2.51(+1.83%)UPDATE 2-ConocoPhillips beats estimates on higher oil prices, raises dividend7:30:23 AM ETCOP$139.45+2.51(+1.83%)ConocoPhillips Q3 profit beats on higher prices, hikes dividend7:26:13 AM ETMETA$635.01+5.01(+0.80%)UPDATE 2-Meta sells first bonds in euros, raises €9 billion7:25:25 AM ETDTE$137.45-0.06(-0.04%)UPDATE 1-DTE Energy to sell its non-utility business for about $3 billion7:23:30 AM ETAAPL$354.00+4.49(+1.28%)Jim Cramer's Surprise Midterm Winner: Apple, Because Fewer Data Centers Could Mean Cheaper Memory7:19:09 AM ETTSLA$376.34-8.85(-2.30%)Ferrari vs. Tesla: Can the Luce Outsell the Roadster?7:18:00 AM ET

SABS · NASDAQ

SAB Biotherapeutics, Inc.

$3.17 0.00 (-0.16%)

Company overview

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune and autoimmune disorders such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully human polyclonal antibody therapeutic candidate in Phase III clinical trial for the treatment of COVID-19, and SAB-176, a fully human polyclonal antibody therapeutic candidate in development to treat or prevent severe influenza.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$288M
Employees
63
Headquarters
Sioux Falls, SD
Website
sabbiotherapeutics.com
CEO
Samuel J. Reich
Listed
February 9, 2021
P/E
7.37
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$3.1M
Operating income
-$58.2M
EBITDA
$1.7M
Net income
-$398,429
EPS
$0.43
Total assets
$248M
Total debt
$6.2M
Earnings yield
13.56%

Revenue segmentation

By product (FY 2022)
By region (FY 2022)

No geographic segmentation.

Showing FY 2022

Price chart

2.352.943.524.104.68
SABS 1D NASDAQ O3.17H3.34L3.09C3.18+0.05 (+1.76%)Vol987.10K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
SABSSAB Biotherapeutics, Inc. Press release SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights GlobeNewswire
SABSSAB Biotherapeutics, Inc. Press release SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET GlobeNewswire
SABSSAB Biotherapeutics, Inc. Stock news SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform MarketBeat
SABSSAB Biotherapeutics, Inc. Press release SAB BIO to Participate in Chardan 10th Annual Healthcare Conference GlobeNewswire
SABSSAB Biotherapeutics, Inc. Press release SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes GlobeNewswire
SABSSAB Biotherapeutics, Inc. Press release SAB BIO to Present SAB-142 Data at the Inaugural GlobeNewswire
SABSSAB Biotherapeutics, Inc. Stock news SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Rated “Moderate Buy” by Sell-Side Analysts Defense World
SABSSAB Biotherapeutics, Inc. Press release SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting GlobeNewswire
SABSSAB Biotherapeutics, Inc. Stock news SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Seeking Alpha
SABSSAB Biotherapeutics, Inc. Press release SAB BIO to Participate in Upcoming Investor Conferences GlobeNewswire
SABSSAB Biotherapeutics, Inc. Stock news SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages Defense World
SABSSAB Biotherapeutics, Inc. Stock news SAB Biotherapeutics Q1 Earnings Call Highlights MarketBeat
SABSSAB Biotherapeutics, Inc. Press release SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights GlobeNewswire
SABSSAB Biotherapeutics, Inc. Press release SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET GlobeNewswire
SABSSAB Biotherapeutics, Inc. Press release SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026 GlobeNewswire
SABSSAB Biotherapeutics, Inc. Stock news SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes Seeking Alpha
SABSSAB Biotherapeutics, Inc. Press release SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire
SABSSAB Biotherapeutics, Inc. Press release SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire
SABSSAB Biotherapeutics, Inc. Press release SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire
SABSSAB Biotherapeutics, Inc. Press release SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes GlobeNewswire
See more
FAQ

Questions about SAB Biotherapeutics, Inc.

What does SAB Biotherapeutics, Inc. do?
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune and autoimmune disorders such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully human polyclonal antibody therapeutic candidate in Phase III clinical trial for the treatment of COVID-19, and SAB-176, a fully human polyclonal antibody therapeutic candidate in development to treat or prevent severe influenza.
What is SABS's market cap?
SAB Biotherapeutics, Inc. (SABS) is a listed stock with a live quote. The latest market cap on this page is $288M.
Where is SAB Biotherapeutics, Inc. headquartered?
SAB Biotherapeutics, Inc. is headquartered in Sioux Falls, SD.
How do I get SABS news from the API?
Call GET /v1/news?tickers=SABS. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does SABS news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for SABS, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the SABS price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs